| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1870 | |
| Phytochemical name or plant extracts | Norstictic acid | |
| PMID | 26744260 | |
| Literature evidence | The anticancer-guided fractionation of Usnea strigosa (Ach.) lichen extract led to the identification of the depsidone-derived norstictic acid as a novel bioactive hit against breast cancer cell lines. | |
| IUPAC name | 5,13,17-trihydroxy-7,12-dimethyl-9,15-dioxo-2,10,16-trioxatetracyclo[9.7.0.03,8.014,18]octadeca-1(11),3(8),4,6,12,14(18)-hexaene-4-carbaldehyde | |
| Phytochemicals’ class or type of plant extracts | Depsidone-derived | |
| Source of phytochemicals or plant Extracts | Usnea strigosa | |
| Geographical availability | NA | |
| Plant parts | NA | |
| Other cancers | Breast cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | Norstictic acid significantly suppressed the TNBC MDA-MB-231 cell proliferation, migration, and invasion, with minimal toxicity to non-tumorigenic MCF-10A mammary epithelial cells. | |
| Cell line/ mice model | MDA-MB-231 | |
| Additional information | Norstictic acid treatment significantly suppressed MDA-MB-231/GFP tumor growth of a breast cancer xenograft model in athymic nude mice. Lichen-derived natural products are promising resources to discover novel c-Met inhibitors useful to control TNBCs. | |
| PubChem ID | 5379540 | |
| Additional PMIDs | NA | |
| Additional sources of information | NA | |
| Safety | NA |